IP Library › Granted Patent US 12,344,647
Granted Patent B2
US 12,344,647 · App. 18/053,671 · Granted Jul 1, 2025

Formulation of modified interleukin-7 fusion protein

Inventors: Donghoon Choi (Seongnam-si, KR); Changyong Eun (Seoul, KR); Seong Hoon Jeong (Goyang-si, KR); Jun Yeul Lim (Busan, KR)
Assignee: Genexine, Inc.
C07K14/5418A61K9/08A61K38/2046A61K47/10A61K47/12A61K47/183A61K47/26C07K7/06C07K14/54C07K5/06026C07K5/0606C07K5/0806C07K5/081C07K5/1008C07K5/1013C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,344,647
App. No.
18/053,671
Granted
Jul 1, 2025
Kind
B2
Abstract

Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v %; and (d) a surfactant with a concentration of 0.05 to 6 w/v %. Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.

Claims (20)

1. A pharmaceutical formulation comprising: (a) an interleukin-7 (IL-7) fusion protein, which comprises an IL-7 protein which is conjugated to a Fe region of an immunoglobulin; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v %; and (d) a surfactant with a concentration of 0.05 to 6 w/v %; wherein the IL-7 fusion protein further comprises an oligopeptide selected from the group consisting of M, G, MM, MG, GM, GG, MMM, GMM, MGM, MMG, GGM, GMG, MGG, GGG, MMMM (SEQ ID NO: 9), GMMM (SEQ ID NO: 10), MGMM (SEQ ID NO: 11), MMGM (SEQ ID NO: 12), MMMG (SEQ ID NO: 13), GGMM (SEQ ID NO: 14), MGGM (SEQ ID NO: 15), MMGG (SEQ ID NO: 16), GMGM (SEQ ID NO: 17), MGMG (SEQ ID NO: 18), GMMG (SEQ ID NO: 19), GGGM (SEQ ID NO: 20), MGGG (SEQ ID NO: 21), GMGG (SEQ ID NO: 22), GGMG (SEQ ID NO: 23), GGGG (SEQ ID NO: 24), MMMMM (SEQ ID NO: 25), GMMMM (SEQ ID NO: 26), GGMMM (SEQ ID NO: 27), GGGMM (SEQ ID NO: 28), GGGGM (SEQ ID NO: 29), MGMMM (SEQ ID NO: 30), MGGMM (SEQ ID NO: 31), MGGGM (SEQ ID NO: 32), MGGGG (SEQ ID NO: 33), MMGMM (SEQ ID NO: 34), MMGGM (SEQ ID NO: 35), MMGGG (SEQ ID NO: 36), MMMGM (SEQ ID NO: 37), MMMGG (SEQ ID NO: 38), MMMMG (SEQ ID NO: 39), MGGGM (SEQ ID NO: 40), MGMGM (SEQ ID NO: 41), GMGMG (SEQ ID NO: 42), GMMMG (SEQ ID NO: 43), GGMGM (SEQ ID NO: 44), GGMMG (SEQ ID NO: 45), MGGMG (SEQ ID NO: 46), MGMGG (SEQ ID NO: 47), GMMGM (SEQ ID NO: 48), MGMMG (SEQ ID NO: 49), GMGGM (SEQ ID NO: 50), MMGMG (SEQ ID NO: 51), GMMGG (SEQ ID NO: 52), GMGGG (SEQ ID NO: 53), GGMGG (SEQ ID NO: 54), GGGMG (SEQ ID NO: 55), and GGGGG (SEQ ID NO: 56); wherein the IL-7 protein comprises: (i) amino acid residues 26-177 of the sequence set forth in SEQ ID NO: 1, (ii) amino acid residues 26-154 of the sequence set forth in SEQ ID NO: 2, (iii) amino acid residues 26-154 of the sequence set forth in SEQ ID NO: 3, (iv) amino acid residues 26-8177 of the sequence set forth in SEQ ID NO: 4, (v) amino acid residues 26-176 of the sequence set forth in SEQ ID NO: 5, or (iv) amino acid residues 26-176 of the sequence set forth in SEQ ID NO:6; and wherein the Fc region of the immunoglobulin has the amino acid sequence set forth in SEQ ID NO: 7.

2. The pharmaceutical formulation of claim 1 , wherein the oligopeptide is bound to the N-terminal of the IL-7 protein.

3. The pharmaceutical formulation of claim 1 , wherein the Fe region of the immunoglobulin is bound to the C-terminal of the IL-7 protein.

4. The pharmaceutical formulation of claim 1 , wherein the basal buffer is histidine-acetate or sodium citrate.

5. The pharmaceutical formulation of claim 1 , wherein the sugar is selected from the group consisting of sucrose, trehalose, dextrose, and a mixture thereof.

6. The pharmaceutical formulation of claim 1 , wherein the surfactant is selected from the group consisting of polysorbate, polyoxyethylene alkyl ether, polyoxyethylene stearate, alkyl sulfates, polyvinyl pyridone, poloxamer and a mixture thereof.

7. The pharmaceutical formulation of claim 1 , further comprising any one amino acid selected from the group consisting of arginine, glutamate, glycine, histidine, and a mixture thereof.

8. The pharmaceutical formulation of claim 7 , wherein the concentration of the amino acid ranges from 40 to 60 mM.

9. The pharmaceutical formulation of claim 8 , wherein the concentration of the amino acid is 50 mM.

10. The pharmaceutical formulation of claim 1 , further comprising a sugar alcohol, wherein the sugar alcohol is at a concentration of 1 to 2 w/v %.

11. The pharmaceutical formulation of claim 10 , wherein the sugar alcohol is selected from the group consisting of sorbitol, xylitol, maltitol, mannitol, and a mixture thereof.

12. The pharmaceutical formulation of claim 1 , wherein the pH of the formulation is 5.0.

13. The pharmaceutical formulation of claim 1 , wherein the formulation is a liquid formulation.

14. The pharmaceutical formulation of claim 1 , wherein the IL-7 protein comprises amino acid residues 26-178 of the sequence set forth in SEQ ID NO: 1.

15. The pharmaceutical formulation of claim 1 , wherein the formulation does not comprise any one amino acid selected from the group consisting of arginine, glutamate, glycine, histidine, and a mixture thereof.

16. The pharmaceutical formulation of claim 15 , wherein the formulation does not comprise histidine.

17. The pharmaceutical formulation of claim 1 , wherein the oligopeptide is bound to the N-terminal of the IL-7 protein and the Fc region of the immunoglobulin is bound to the C-terminal of the IL-7 protein.

18. The pharmaceutical formulation of claim 1 , wherein the IL-7 fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 8.

19. The pharmaceutical formulation of claim 18 , wherein: (a) the basal buffer is histidine-acetate or sodium citrate; (b) the sugar is selected from the group consisting of sucrose, trehalose, dextrose, and a mixture thereof; (c) wherein the surfactant is selected from the group consisting of polysorbate, polyoxyethylene alkyl ether, polyoxyethylene stearate, alkyl sulfates, polyvinyl pyridone, poloxamer and a mixture thereof; (d) an amino acid selected from the group consisting of arginine, glutamate, glycine, histidine, and a mixture thereof; (e) a sugar alcohol; or (f) any combination of (a) to (e).

20. The pharmaceutical formulation of claim 19 , wherein: (a) the amino acid is present at a concentration of 40 to 60 mM; (b) the sugar alcohol is at a concentration of 1 to 2 w/v %; (c) the pH is 5.0; or (d) any combination of (a) to (c).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2025
From: CHOI, DONGHOON; EUN, CHANGYONG; JEONG, SEONG HOON; LIM, JUN YEUL
To: GENEXINE, INC.
Reel/Frame 070339/0884 →
Priority Claims (1)
KR 10-2015-0156124 · Nov 6, 2015 · national
Continuity (2)
Continuation 15773273
Related Publication 20230279069A1 · Sep 7, 2023
References Cited (86)
US 5093242A · Bachmair et al. · 1992 [cited by applicant]
US 6153380A · Nolan et al. · 2000 [cited by applicant]
US 7585947B2 · Morre et al. · 2009 [cited by applicant]
US 7589179B2 · Gillies et al. · 2009 [cited by applicant]
US 8153114B2 · Morre et al. · 2012 [cited by applicant]
US 10208009B2 · Rho et al. · 2019 [cited by applicant]
US 10208099B2 · Yang et al. · 2019 [cited by applicant]
US 11357827B2 · Kang et al. · 2022 [cited by applicant]
US 11548927B2 · Choi et al. · 2023 [cited by applicant]
US 11708399B2 · Kang et al. · 2023 [cited by applicant]
US 20020127564A1 · Nolan · 2002 [cited by applicant]
US 20050054054A1 · Foss · 2005 [cited by examiner]
US 20050164352A1 · Lauder · 2005 [cited by examiner]
US 20050249701A1 · Morre et al. · 2005 [cited by applicant]
US 20060141581A1 · Gillies · 2006 [cited by examiner]
US 20080206190A1 · Morre et al. · 2008 [cited by applicant]
US 20080300188A1 · Yang · 2008 [cited by examiner]
US 20100196312A1 · Morre et al. · 2010 [cited by applicant]
US 20110243887A1 · Lauder et al. · 2011 [cited by applicant]
US 20120016104A1 · Morre et al. · 2012 [cited by applicant]
US 20130217864A1 · Cho et al. · 2013 [cited by applicant]
US 20140178393A1 · Andres et al. · 2014 [cited by applicant]
US 20140377218A1 · Morre et al. · 2014 [cited by applicant]
US 20150306224A1 · Krause et al. · 2015 [cited by applicant]
CN 105012949A · 2015 [cited by applicant]
EP 0314415A2 · 1989 [cited by applicant]
EP 0877752B1 · 2003 [cited by applicant]
JP H02501618A · 1990 [cited by applicant]
JP 250198618B2 · 1996 [cited by applicant]
JP 2000504220A · 2000 [cited by applicant]
JP 2001509661A · 2001 [cited by applicant]
JP 2009501543A · 2009 [cited by applicant]
JP 2010531134A · 2010 [cited by applicant]
JP 2014147396A · 2014 [cited by applicant]
JP 201557392A · 2015 [cited by applicant]
KR 1020060112673A · 2006 [cited by applicant]
KR 1020090045953A · 2009 [cited by applicant]
KR 1020120041139A · 2012 [cited by applicant]
KR 1020140004802A1 · 2014 [cited by applicant]
KR 1020170066265A · 2017 [cited by applicant]
WO WO8802406A · 1988 [cited by applicant]
WO WO2005021592A2 · 2005 [cited by applicant]
WO WO2009101737A1 · 2011 [cited by applicant]
WO WO2015015516A2 · 2015 [cited by applicant]
WO WO2007019232A2 · 2017 [cited by examiner]
WO WO2017078385A1 · 2017 [cited by applicant]
Bowie et al. Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions. Science, 1990, 247:1306-1310 (Year: 1990). [cited by examiner]
Burgess et al. Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single L… [cited by examiner]
Lazar et al. Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities. Mol. Cell. Biol., 8:1247-1252, 1988 (Year: 1988). [cited by examiner]
Bork. Powers and Pitfalls in Sequence Analysis: The 70% Hurdle. Genome Research, 2000; 10:398-400 (Year: 2000). [cited by examiner]
Greenspan et al. 1999. Defining epitopes: It's not as easy as it seems; Nature Biotechnology, 17:936-937 (Year: 1999). [cited by examiner]
NCBI, PDB: 4C54_A (Feb. 5, 2014), “Chain A, Crystal Structure of Recombinant Human IgG4 Fc”. [cited by applicant]
International Search Report for International Application No. PCT/KR2016/012495, Korean Intellectual Property Office, Republic of Korea, mailed on Jan. 13, 2017, 4 pages. [cited by applicant]
Fry, T., and Mackall C.L, “Interleukin-7: from bench to clinic,” Blood 99(11):3892-3904, American Society of Hematology, United States (Jun. 2002). [cited by applicant]
GenBank, “Interleukin-7 [synthetic construct],” Accession No. AAB70834.1, accessed at https://www.ncbi.nlm.nih.gov/protein/AAB70834.1/, accessed on Apr. 28, 2023, 1 page. [cited by applicant]
Heufler, C., et al., “Interleukin 7 is produced by murine and human keratinocytes,” J Exp Med 178(3):1109-1114, Rockefeller University Press, United States (Sep. 1993). [cited by applicant]
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority issued Dec. 12, 2017 for related PCT/KR2016/006214. [cited by applicant]
International Search Report for International Application No. PCT/KR2016/006214, Korean Intellectual Property Office, Republic of Korea, mailed on Aug. 24, 2016, 6 pages. [cited by applicant]
Kroncke, R., et al., “Human follicular dendritic cells and vascular cells produce interleukin-7: a potential role for interleukin-7 in the germinal center reaction,” Eur J Immunol 26(10):2541-2544, Wiley-VCH, Germany (O… [cited by applicant]
Pellegrini, M., et al., “IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology,” Cell 144(4):601-613, Cell Press, United States (Feb. 2011). [cited by applicant]
Muegge, K., et al., “Interleukin-7: a cofactor for V(D)J rearrangement of the T cell receptor beta gene,” Science 261(5117):93-95, American Association for the Advancement of Science, United States (Jul. 1993). [cited by applicant]
Nanjappa, S., et al., “Immunotherapeutic effects of IL-7 during a chronic viral infection in mice,” Blood 117(19):5123-5132, American Society of Hematology, United States (May 2011). [cited by applicant]
Patel, A., et al., “Treatment of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia,” J Antimicrob Chemother 65(12):2489-2492, Oxford University Press, United Kingdom (Dec. 2010). [cited by applicant]
Pellegrini, M., et al., “Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies,” Nat Med 15(5):528-536, Nature Portfolio, Germany (May 2009). [cited by applicant]
Rosenberg, S., et al., “IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells,” J Immunother 29(3):313-319, Lippincott Williams & Wilkins, United Stat… [cited by applicant]
Sawa, Y., et al., “Hepatic interleukin-7 expression regulates T cell responses,” Immunity 30(3):447-457, Cell Press, United States (Mar. 2009). [cited by applicant]
Snyder, K.M., et al., “IL-7 in allogeneic transplant: clinical promise and potential pitfalls,” Leuk Lymphoma 47(7):1222-1228, Informa, United Kingdom (Jul. 2006). [cited by applicant]
Watanabe, M., et al., “Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes,” J Clin Invest 95(6):2945-2953, American Society for Clinical Inve… [cited by applicant]
European Patent Office; Search Report dated Dec. 19, 2018 issued in Counterpart U.S. Appl. No. 16/807,859. [cited by applicant]
Japanese Patent Office; Search Report dated Jan. 8, 2019 issued in Counterpart Application No. 2017-564121. [cited by applicant]
European Patent Office; Communication dated May 15, 2019 in Counterpart Application No. 16807859.0. [cited by applicant]
Mikayama, T., et al., “Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor,” Proc Natl Acad Sci USA 90(21):10056-10060, National Academy of Sciences, United States (Nov. 1993). [cited by applicant]
Voet et al., Biochemistry John Wiley & Sons Inc. (1990) pp. 126-128 and 228-234. [cited by applicant]
International Search Report for International Application No. PCT/KR2016/013966, Korean Intellectual Property Office, Republic of Korea, mailed on Mar. 2, 2017, 4 pages. [cited by applicant]
Moon Cheol Kang, et al., “Intranasal Introduction of Fc-Fused Interleukin-7 Provides Long-Lasting Prophylaxis against Lethal Influenza Virus Infection,” J Virol 90(5):2273-2284, American Society of Microbiology, United … [cited by applicant]
Nam, H.J., et al., “Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant,” Eur J Immunol 40(2):351-358, Wiley-VCH, Germany (Feb. 2010). [cited by applicant]
Yong Bok Seo, et al., “Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity,” J Virol 88(16):8998-9009, American Society of Microbiology, United States … [cited by applicant]
Bowie, J., et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,” Science 247(4948):1306-1310, American Association for the Advancement of Science, United States (Mar. 1990). [cited by applicant]
Burgess, W.H., et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a… [cited by applicant]
Lazar, E., et al., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities,” Mol Cell Biol 8(3):1247-1252, American Society for Microbiology, United Stat… [cited by applicant]
Bork, P., “Powers and pitfalls in sequence analysis: the 70% hurdle,” Genome Res 10(4):398-400, Cold Spring Harbor Laboratory Press, United States (Apr. 2000). [cited by applicant]
International Search Report for International Application No. PCT/KR2016/014127, Korean Intellectual Property Office, Republic of Korea, mailed on Mar. 9, 2017, 4 pages. [cited by applicant]
Whisstock, J., and Lesk, A., “Prediction of protein function from protein sequence and structure,” Q Rev Biophys 36(3):307-340, Cambridge University Press, United Kingdom (Aug. 2003). [cited by applicant]
Maryam Fazeli et al., “Efficacy of HPV-16 E7 Based Vaccine in a TC-1 Tumoric Animal Model of Cervical Cancer,” Cell Journal 12(4):483-488, Cell Press, United States (2011). [cited by applicant]
Greenspan, N.S., et al., “Defining epitopes: It's not as easy as it seems,” Nature Biotechnology, 17:936-937, Springer, Germany (Oct. 1999). [cited by applicant]
Buchman, A., et al., “Comparison of Intron-Dependent and Intron-Independent Gene Expression,” Molecular and Cellular Biology 8(10):4395-4405, American Society for Microbiology, United States (Oct. 1988). [cited by applicant]